Adverse events following immunization (AEFI) in patients with Primary Immunodeficiencies.

Abstract

Event Abstract Back to Event Adverse events following immunization (AEFI) in patients with Primary Immunodeficiencies. Juan D. Sarmiento Delgado1, Claudia M. Trujillo Vargas1*, Fabio A. Villada1, Julio C. Orrego Arango1 and Jose L. Franco1 1 Universidad de Antioquia, Grupo de Inmunodeficiencias Primarias, Colombia Introduction. Adverse Events Following Immunization (AEFI) require special consideration in patients with Primary Immunodeficiency Diseases (PID) because they represent in many cases the “red flag” for the initial diagnosis of the disease, determine prognosis and complications and help to define appropriate vaccination schemes according to the type of PID. Objective. The aim of this study is to describe the epidemiologic pattern of AEFI in a cohort of patients with PID. Methods. This study included 379 medical records from PID patients. The AEFI severity was classified according to the WHO 1999 guidelines in: common, minor, rare and more serious vaccine reactions. The assessment of causality was performed following the CISA-2009 criteria. Results. Evidence of AEFI was found in 26 medical records (7% of the PID medical records analyzed, 84% males) and represented a total of 29 reactions. AEFI occurred before or at the same age of the PID diagnosis in most patients. Idiopathic hypogammaglobulinemia (IHG), CGD and SCID were the disorders more susceptible to present with AEFI with 10, 4 and 4 cases, respectively. A total of 24 reactions were associated to replicative vaccines, 7 and 10 with BCG and OPV respectively, and the rest related to MMR, Haemophilus influenzae or varicella vaccination. BCG was the vaccine more often associated to definitive AEFI in PID. Conclusions. Our findings revealed increased risk of serious AEFI in patients with PID. The overall risk varies depending on the vaccine applied and the underlying condition of the patient. The risk of AEFI increased after the administration of live compared with non-live vaccines. Our study also described the increased risk of seizures in PID patients vaccinated with DPT. Clinical Implications: Information about the AEFI in vaccines circulating in the immunization schemes of vulnerable population such as PID patients, might represent a tremendous tool to decrease the burden of these diseases and are essential for their timely diagnosis, appropriate management and improve prognosis. Keywords: Primary Immunodeficiency Diseases, Live vaccines, non-live vaccines, Adverse events following immunization, BCG Vaccine Conference: IMMUNOCOLOMBIA2015 - 11th Congress of the Latin American Association of Immunology - 10o. Congreso de la Asociación Colombiana de Alergia, Asma e Inmunología, Medellin, Colombia, 13 Oct - 16 Oct, 2015. Presentation Type: Poster Presentation Topic: Immunodeficiencies Citation: Sarmiento Delgado JD, Trujillo Vargas CM, Villada FA, Orrego Arango JC and Franco JL (2015). Adverse events following immunization (AEFI) in patients with Primary Immunodeficiencies.. Front. Immunol. Conference Abstract: IMMUNOCOLOMBIA2015 - 11th Congress of the Latin American Association of Immunology - 10o. Congreso de la Asociación Colombiana de Alergia, Asma e Inmunología. doi: 10.3389/conf.fimmu.2015.05.00124 Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters. The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated. Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed. For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions. Received: 12 May 2015; Published Online: 14 Sep 2015. * Correspondence: PhD. Claudia M Trujillo Vargas, Universidad de Antioquia, Grupo de Inmunodeficiencias Primarias, Medellin, Colombia, cmtruji@gmail.com Login Required This action requires you to be registered with Frontiers and logged in. To register or login click here. Abstract Info Abstract The Authors in Frontiers Juan D Sarmiento Delgado Claudia M Trujillo Vargas Fabio A Villada Julio C Orrego Arango Jose L Franco Google Juan D Sarmiento Delgado Claudia M Trujillo Vargas Fabio A Villada Julio C Orrego Arango Jose L Franco Google Scholar Juan D Sarmiento Delgado Claudia M Trujillo Vargas Fabio A Villada Julio C Orrego Arango Jose L Franco PubMed Juan D Sarmiento Delgado Claudia M Trujillo Vargas Fabio A Villada Julio C Orrego Arango Jose L Franco Related Article in Frontiers Google Scholar PubMed Abstract Close Back to top Javascript is disabled. Please enable Javascript in your browser settings in order to see all the content on this page.